UICC & ISOPP Joint Statement: Ensuring quality and equity in cancer treatment

📢 New Joint Statement from International Society of Oncology Pharmacy Practitioners (ISOPP) and Union for International Cancer Control (UICC)

Substandard and falsified (SF) cancer medicines are jeopardising treatment outcomes and patient safety in low- and middle-income countries. A recent study published in The Lancet Global Health revealed that 1 in 6 chemotherapy medicines sampled in sub-Saharan Africa failed to meet international standards.

In response, ISOPP and UICC have issued a joint statement calling for urgent global action to strengthen medicine quality across the supply chain—from regulation and procurement to delivery and use.

📌 Read the full statement and join us in advocating for equitable, high-quality cancer care:

đź”— Statement: https://lnkd.in/eKbQK_vc and https://lnkd.in/e23ppHDG
đź”— Publication: https://lnkd.in/eE8fXkSx

Latest News

By Suriya Marshall on 14th March 2026

Parliamentary Intervention Sparks National Campaign to Protect NHS Staff from Hazardous Medicinal Products (HMPs)

First UK Campaign to Protect Healthcare Workers from Exposure to Hazardous Medicinal Products (HMPs) launches in Westminster London, 10 March 2026: Today, the Safer Healthcare and Biosafety Network (SHBN) launches…

Read article
By Suriya Marshall on 14th March 2026

Clinical Pharmacy Congress. 8th-9th May 2026

Dear BOPA member, We are excited to announce that we have partnered with Clinical Pharmacy Congress 2026. Clinical Pharmacy Congress is the UK’s leading event for clinical pharmacy professionals working across…

Read article
By BOPA Executive Committee on 13th March 2026

First UK Campaign to Protect Healthcare Workers from Exposure to Hazardous Medicinal Products (HMPs) launches in Westminster

London, 10 March 2026: The Safer Healthcare and Biosafety Network (SHBN) launches a new campaign titled “Protecting Healthcare Workers: Safer Handling of Hazardous Medicinal Products” to raise awareness of the dangers…

Read article
By BOPA on 13th March 2026

Invitation to Participate: SWEET-PLUS Study

You are invited to take part in a research study called SWEET-PLUS (NIHR Research for Patient Benefit: 207952), run by Newcastle and Oxford Brookes Universities. SWEET-PLUS aims to understand experiences…

Read article